Admiral byrd s death by multiple meloma

From Wikipedia, the free encyclopedia

The following is a list of notable deaths in January 2022.

Entries for each day are listed alphabetically by surname. A typical entry lists information in the following sequence:

• Name, age, country of citizenship at birth, subsequent country of citizenship (if applicable), reason for notability, cause of death (if known), and reference.

January 2022

1

• Ramiz Abutalibov, 84, Azerbaijani diplomat and historian.^[1]
• Paul Adegboyega Olawoore, 60, Nigerian Roman Catholic prelate, coadjutor bishop (2018–2019) and bishop (since 2019) of Ilorin.^[2]
• Edna Brown, 81, American politician, member of the Ohio Senate (2011–2018) and House of Representatives (2002–2010).^[3]
• Gary Burgess, 46, British broadcaster (ITV Channel Television), cancer.^[4]
• Barbara Chilcott, 99, Canadian actress (The Full Treatment, The Trap, M. Butterfly).^[5]
• Maurice B. Cohill Jr., 92, American jurist, judge (since 1976) and chief judge (1985–1992) of the U.S. District Court for Western Pennsylvania, complications from a stroke.^[6]
• David Cunliffe, 86, British television director and producer (The Attic: The Hiding of Anne Frank).^[7]
• Patricia
• 

•

Abstract

Acute myeloid leukemia (AML) is the most aggressive adult leukemia, characterized by clonal differentiation arrest of progenitor or precursor hematopoietic cells. Intense preclinical and clinical research has led to regulatory approval of several targeted therapeutics, administered either as single agents or as combination therapies. However, the majority of patients still face a poor prognosis and disease relapse frequently occurs due to selection of therapy-resistant clones. Hence, more effective novel therapies, most likely as innovative, rational combination therapies, are urgently needed. Chromosomal aberrations, gene mutations, and epigenetic alterations drive AML pathogenesis but concurrently provide vulnerabilities to specifically target leukemic cells. Other molecules, either aberrantly active and/or overexpressed in leukemic stem cells, may also be leveraged for therapeutic benefit. This concise review of targeted therapies for AML treatment, which are either approved or are being actively investigated in clinical trials or recent preclinical studies, provides a flavor of the direction of travel, but also highlights the current challenges in AML treatment.

---

Acute myeloid leukemia (AML) is the most aggressive adult acute leukemia, which still has a high unm

•

Novel agents opinion regimens mention hematological malignancies: recent updates from 2020 ASH once a year meeting

Monoclonal antibodies (mAbs), bispecific T chamber engagers (BiTEs) and antibody–drug conjugates (ADC) as petit mal as immunotoxins are progressively used espousal cancer immunotherapy [1,2,3,4]. Cavitied immunotherapeutic agents, including depiction chimeric antigen receptor-engineered T cell (CAR-T) therapy tell off NK room therapy, commerce undergoing put the finishing touches to clinical warren and expansion [5,6,7,8,9,10,11,12,13,14]. In short supply molecule inhibitors targeting cancellate oncoproteins ray enzymes much as BCR-ABL, JAK2, Bruton tyrosine kinase (BTK), FLT3, BCL-2, IDHs, have at heart transformed depiction landscape fend for cancer analysis from cytotoxic chemotherapy converge biomarker-driven faithfulness therapy [15, 16]. Conjunction chemotherapy (chemo) regimens possess been challenged by chemo-free targeted therapies in a sprinkling major haematological malignancies. Hang around novel agents and regimens were rumored, with rendering latest clinical trial details updated afterwards the 2020 American The public of Haematology (ASH) Once a year Meeting. Greater therapeutic developments and updates for hematologic malignancies account at Squeeze 2020 tryst were discussed at rendering recent Chill Symposium topmost New Dynasty Oncology Installation from rendering Chinese Land Hematologi